Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Capital Expenditures (2021 - 2024)

Historic Capital Expenditures for Verrica Pharmaceuticals (VRCA) over the last 4 years, with Q3 2024 value amounting to $16000.0.

  • Verrica Pharmaceuticals' Capital Expenditures fell 7538.46% to $16000.0 in Q3 2024 from the same period last year, while for Sep 2025 it was $27000.0, marking a year-over-year decrease of 8937.01%. This contributed to the annual value of $27000.0 for FY2024, which is 9254.14% down from last year.
  • As of Q3 2024, Verrica Pharmaceuticals' Capital Expenditures stood at $16000.0, which was down 7538.46% from $11000.0 recorded in Q2 2024.
  • Verrica Pharmaceuticals' Capital Expenditures' 5-year high stood at $311000.0 during Q1 2021, with a 5-year trough of $5000.0 in Q1 2022.
  • Over the past 4 years, Verrica Pharmaceuticals' median Capital Expenditures value was $65500.0 (recorded in 2022), while the average stood at $112428.6.
  • In the last 5 years, Verrica Pharmaceuticals' Capital Expenditures plummeted by 9839.23% in 2022 and then surged by 24393.94% in 2023.
  • Quarter analysis of 4 years shows Verrica Pharmaceuticals' Capital Expenditures stood at $237000.0 in 2021, then crashed by 72.15% to $66000.0 in 2022, then soared by 243.94% to $227000.0 in 2023, then plummeted by 92.95% to $16000.0 in 2024.
  • Its last three reported values are $16000.0 in Q3 2024, $11000.0 for Q2 2024, and $227000.0 during Q4 2023.